11.01.2023 - Company aims to commercialize wholly-owned KETARX (racemic ketamine) for mental health, neurological and pain disorders Company aims to seek FDA approvals for KETARX via the ANDA and 505(b)(2) regulatory pathways in H2-2023 Company aims . Seite 1
(2022-11-15 | CSE:DMED) DiagnaMed Holdings Acquires Exclusive Rights to a Virtual Reality and Artificial Intelligence-based Neurodiagnostic System for Neurodegenerative Disease
Exclusive license of intellectual property from the University of Kansas of a proprietary diagnostic tool combining artificial intelligence and virtual.
The technology emulates a real-world environment to emulate common daily tasks to help measure a patient’s ability to fixate on a point, conduct smooth pursuit of an object, or execute saccades.